Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Endocrine ; 85(3): 1131-1140, 2024 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-38842765

RESUMEN

BACKGROUND: Despite enormous advances in diabetes treatment, women with type 1 diabetes mellitus (DM) still experience delayed menarche, menstrual irregularities, fewer pregnancies, and a higher rate of stillbirths compared to women without the disease. Due to the fact that type 1 DM occurs at a young age, the preservation of reproductive health is one of the most important goals of treatment. AIMS: The aim of this study was to evaluate the relationship between different glycemic profiles and changes in the pro-oxidant-antioxidant balance and ovarian follicular apparatus in reproductive-age patients with type 1 DM. METHODS: We examined 50 reproductive-age (19-38 years) women with type 1 DM with a disease duration of at least ten years. Carbohydrate metabolism was assessed with the continuous glucose monitoring (CGM) system and glycated hemoglobin (HbA1c) concentration measurement. CGM was performed using the FreeStyle Libre flash glucose monitoring system (Abbott Diabetes Care, Witney, UK). In each patient, malondialdehyde level, catalase activity and 3-nitrotyrosine level in the blood serum were determined. To assess the ovarian function, we measured the ovarian volume, the antral follicle count, and the serum levels of anti-Müllerian hormone and follicle-stimulating hormone. All patients were divided into four groups (glucotypes) based on the CGM results. Group 1 included type 1 DM patients with satisfactory compensation of carbohydrate metabolism; group 2 consisted of patients with frequent hypoglycemic conditions and pathological glucose variability; group 3 included individuals with prolonged hyperglycemic conditions and maximum HbA1c levels; and group 4 comprised patients with the glycemic profile characterized by all the presented types of dysglycemia (intermittent glycemia). RESULTS: We revealed a negative correlation between serum catalase activity and time of hypoglycemic conditions in patients with type 1 DM based on the CGM results (rs = -0.47, p < 0.01). In group 4 (intermittent glycemia), patients demonstrated the lowest serum catalase activity and increased serum 3-nitrotyrosine level, while in group 3, women with chronic hyperglycemia (HbA1c 8.4 [8.1; 9.9]%; 68 [65; 85] mmol/mol) had a moderate change in antioxidant defense and oxidative stress parameters. Correlation analysis of ovarian volume, the antral follicle count, and the serum anti-Müllerian hormone level in type 1 DM women with different glycemic profiles established a negative relationship (rs = -0.82, p < 0.05) between the antral follicle count and glucose variability in group 1, a positive relationship (rs = 0.68, p < 0.05) between ovarian volume and glucose variability in group 2, and a positive relationship (rs = 0.88, p < 0.05) between ovarian volume and time of hypoglycemic conditions, which, according to the CGM results, amounted to a critical value of 57.5 [40.0; 82.0]%. CONCLUSIONS: The data obtained indicate the relationship between the ovarian volume, serum anti-Müllerian hormone level, the antral follicle count and oxidative stress parameters not only in patients with hyperglycemia, but also in those with hypoglycemic conditions, as well as with pathological glucose variability.


Asunto(s)
Glucemia , Diabetes Mellitus Tipo 1 , Hemoglobina Glucada , Folículo Ovárico , Estrés Oxidativo , Humanos , Femenino , Diabetes Mellitus Tipo 1/sangre , Diabetes Mellitus Tipo 1/metabolismo , Diabetes Mellitus Tipo 1/complicaciones , Estrés Oxidativo/fisiología , Adulto , Adulto Joven , Glucemia/análisis , Hemoglobina Glucada/análisis , Catalasa/sangre , Hormona Antimülleriana/sangre , Malondialdehído/sangre , Tirosina/análogos & derivados , Tirosina/sangre
2.
Probl Endokrinol (Mosk) ; 70(2): 103-116, 2024 May 09.
Artículo en Ruso | MEDLINE | ID: mdl-38796767

RESUMEN

On March 28, 2024, the Council of Experts "High-dose vitamin D (Devilam) in the practice of obstetrician-gynecologist, gynecologist and endocrinologist" was held in Moscow with the participation of leading experts gynecologists, endocrinologists and obstetricians-gynecologists, during which new possibilities for the use of high-dose vitamin D in patients of various ages who need correction of existing vitamin D deficiency or insufficiency.


Asunto(s)
Ginecología , Obstetricia , Deficiencia de Vitamina D , Vitamina D , Humanos , Vitamina D/administración & dosificación , Vitamina D/uso terapéutico , Deficiencia de Vitamina D/tratamiento farmacológico , Femenino , Embarazo , Ginecólogos , Obstetras
3.
Kardiologiia ; 63(10): 9-28, 2023 Nov 08.
Artículo en Ruso | MEDLINE | ID: mdl-37970852

RESUMEN

Menopausal symptoms can impair the life of women at the peak of their career and family life. At the present time, the most effective treatment for these manifestations is menopausal hormone therapy (MHT). The presence of cardiovascular and metabolic diseases in itself does not exclude the possibility of prescribing MHT to relieve menopausal symptoms and improve quality of life. However, often an obstacle to the use of this type of hormone therapy is the fear of physicians to do more harm to patients than good. Caution is especially important when it comes to women with concurrent diseases. Moreover, it should be recognized that there is a shortage of high-quality research on the safety of MHT for underlying chronic non-infectious diseases and common comorbidities. The presented consensus analyzed all currently available data from clinical trials of various designs and created a set of criteria for the appropriateness of prescribing MHT to women with concomitant cardiovascular and metabolic diseases. Based on the presented document, physicians of various specialties who advise menopausal women will receive an accessible algorithm that will allow them to avoid potentially dangerous situations and reasonably prescribe MHT in real-life practice.


Asunto(s)
Terapia de Reemplazo de Estrógeno , Calidad de Vida , Femenino , Humanos , Terapia de Reemplazo de Estrógeno/efectos adversos , Consenso , Menopausia , Federación de Rusia , Terapia de Reemplazo de Hormonas
4.
Probl Endokrinol (Mosk) ; 69(5): 115-136, 2023 Nov 12.
Artículo en Ruso | MEDLINE | ID: mdl-37968959

RESUMEN

Menopausal symptoms can disrupt the life course of women at the peak of their career and family life. Currently, the most effective treatment for these manifestations is menopausal hormone therapy (MHT). The presence of cardiovascular and metabolic diseases in itself does not exclude the possibility of prescribing MHT to relieve menopausal symptoms and improve quality of life. However, often an obstacle to the use of this type of hormonal therapy is the fear of doctors who are afraid of doing more harm to patients than good. Caution is especially important when it comes to women with underlying health conditions. Moreover, it should be recognized that there is a lack of high-quality research regarding the safety of MHT for major chronic non-infectious diseases and common comorbid conditions. The presented consensus document analyzed all currently available data obtained from clinical trials of various designs and created a set of criteria for the acceptability of prescribing MHT to women with concomitant cardiovascular and metabolic diseases. Based on the presented document, doctors of various specialties who advise women in menopause will receive an accessible algorithm that will allow them to avoid potentially dangerous situations and reasonably prescribe MHT in real practice.


Asunto(s)
Terapia de Reemplazo de Estrógeno , Enfermedades Metabólicas , Humanos , Femenino , Terapia de Reemplazo de Estrógeno/efectos adversos , Ginecólogos , Endocrinólogos , Obstetras , Consenso , Calidad de Vida , Menopausia , Enfermedades Metabólicas/tratamiento farmacológico , Enfermedades Metabólicas/etiología , Hormonas
5.
Probl Endokrinol (Mosk) ; 68(2): 112-127, 2022 02 06.
Artículo en Ruso | MEDLINE | ID: mdl-35488762

RESUMEN

Polycystic ovary syndrome (PCOS) is a polygenic endocrine disorder caused by both genetic and epigenetic factors. Depending on the period of a woman's life, the clinical picture, diagnosis, and treatment tactics of the disease are different. PCOS has a complex of reproductive, metabolic and psychological characteristics. The target audience of these clinical recommendations are obstetrician-gynecologists, endocrinologists, general practitioners, general practitioners. In these clinical guidelines, all information is ranked according to the level of persuasiveness of recommendations and the reliability of evidence, depending on the number and quality of studies on this issue.


Asunto(s)
Síndrome del Ovario Poliquístico , Endocrinólogos , Femenino , Humanos , Síndrome del Ovario Poliquístico/diagnóstico , Síndrome del Ovario Poliquístico/psicología , Síndrome del Ovario Poliquístico/terapia , Reproducibilidad de los Resultados
6.
Probl Endokrinol (Mosk) ; 66(6): 65-73, 2020 Dec 03.
Artículo en Ruso | MEDLINE | ID: mdl-33481369

RESUMEN

There is no universal diagnostic and treatment strategy of subclinical hypothyroidism (SHT) in pregnant women and those who are planning pregnancy due to differences in population-specific and trimester-specific thyroid-stimulating hormone (TSH) reference values, influence of thyroid autoimmunity markers on pregnancy outcomes, adherence to fixed universal cutoff concentrations TSH in Russia and multidisciplinary team care with different treatment opinions involving. An absence of universal approach to SHT leads to excess treatment, financial and psychological burden on pregnant women.Up to American Thyroid Association (ATA) Guidelines 2017 and project of Clinical Guidelines of Russian Association of Endocrinologists 2019 a treatment strategy of SHT should be left up to the endocrinologist to choose. In our paper we systematize global scientific and clinical experience of planning and management pregnancies with SHT to help physicians to choose treatment option based on principals of evidence-based medicine.


Asunto(s)
Hipotiroidismo , Complicaciones del Embarazo , Femenino , Humanos , Hipotiroidismo/diagnóstico , Embarazo , Complicaciones del Embarazo/diagnóstico , Resultado del Embarazo , Primer Trimestre del Embarazo , Tirotropina
7.
Fertil Steril ; 65(5): 961-5, 1996 May.
Artículo en Inglés | MEDLINE | ID: mdl-8612857

RESUMEN

OBJECTIVE: To study the outcome in poor responders to three ampules (225 IU) of hMG per day in subsequent IVF treatment cycles in which six ampules (450 IU)of hMG per day were administered. DESIGN: Retrospective chart review. SETTING: Academic tertiary center. PATIENTS: Between January 1988 and May 1995, 126 poor response patients had a first treatment cycle on three ampules and a second cycle on six ampules of hMG per day. MAIN OUTCOME MEASURES: Numbers of follicles, oocytes, and embryos, and pregnancy rates. RESULTS: On six ampules, patients had significantly more follicles and oocytes. The number of embryos did not differ significantly. The pregnancy rate on six ampules were low (3.2% pregnancies per cycle started). CONCLUSION: Poor responders do not benefit from high-dose hMG stimulation; their reproduction outcome is poor.


Asunto(s)
Fertilización In Vitro , Menotropinas/administración & dosificación , Menotropinas/uso terapéutico , Adulto , Embrión de Mamíferos , Femenino , Hormona Folículo Estimulante/sangre , Humanos , Oocitos/citología , Folículo Ovárico/fisiología , Embarazo , Estudios Retrospectivos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...